SCHEMBL10242894

SCHEMBL10242894

CCCNC(=O)Cc1cccc(-c2ccccn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
CTSL P07711 2/20 0.48
CTSB P07858 1/20 0.48
CTSS P25774 1/20 0.48
FFAR1 O14842 1/20 0.46
WNT3A P56704 8/20 0.45
POLB P06746 1/20 0.45
HRH3 Q9Y5N1 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CTSK P43235 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
PDE4B Q07343 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TRPV1 Q8NER1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6621289 0.88 CTSL (0.47) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL6621286 0.85 CTSL (0.47) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL7408937 0.84 FFAR1 (0.49) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL6620690 0.83 CTSL (0.44) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL1927063 0.83 TRPV1 (0.53) ALDH1A1MEN1KMT2AGAATRPV1
SCHEMBL7463211 0.82 FFAR1 (0.50) CYP4F2CYP4A11CTSLCTSBCTSS
SCHEMBL13537054 0.82 L3MBTL1 (0.58) CYP4F2CYP4A11CTSLCTSBCTSS
SCHEMBL6670621 0.79 CTSL (0.46) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL7816461 0.79 CTSL (0.46) CTSLCTSBCTSSFFAR1WNT3A
SCHEMBL7616026 0.79 CTSL (0.46) CTSLCTSBCTSSFFAR1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 CYP4F2 3682/4885CYP4A11 592/4885CTSL 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.